Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study

Capitanio, 2016, Renal cancer, Lancet, 387, 894, 10.1016/S0140-6736(15)00046-X Ferlay Rini, 2005, Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma, J Clin Oncol, 23, 1028, 10.1200/JCO.2005.01.186 Albiges, 2015, A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer, Eur Urol, 67, 100, 10.1016/j.eururo.2014.04.006 Ratta, 2018, Exposure to multiple lines of treatment and survival of patients with metastatic renal cell carcinoma: a real-world analysis, Clin Genitourin Cancer, 16, e735, 10.1016/j.clgc.2018.01.016 Iacovelli, 2015, Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis, Curr Drug Targets, 16, 164, 10.2174/1389450115666141120120145 Albiges, 2012, Complete remission with tyrosine kinase inhibitors in renal cell carcinoma, J Clin Oncol, 30, 482, 10.1200/JCO.2011.37.2516 McDermott, 2018, Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat Med, 24, 749, 10.1038/s41591-018-0053-3 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Alt, 2011, Survival after complete surgical resection of multiple metastases from renal cell carcinoma, Cancer, 117, 2873, 10.1002/cncr.25836 Kavolius, 1998, Resection of metastatic renal cell carcinoma, J Clin Oncol, 16, 2261, 10.1200/JCO.1998.16.6.2261 Vogl, 2006, Prognostic factors in metastatic renal cell carcinoma: Metastasectomy as independent prognostic variable, Br J Cancer, 95, 691, 10.1038/sj.bjc.6603327 Psutka, 2018, Role of metastasis-directed treatment in kidney cancer, Cancer, 124, 3641, 10.1002/cncr.31341 Eggener, 2008, Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma, J Urol, 180, 873, 10.1016/j.juro.2008.05.006 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809 Han, 2003, Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma, Urology, 61, 314, 10.1016/S0090-4295(02)02163-5 Tosco, 2013, Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma, Eur Urol, 63, 646, 10.1016/j.eururo.2012.09.037 Leibovich, 2005, A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials, J Urol, 174, 1759, 10.1097/01.ju.0000177487.64651.3a Dabestani, 2014, Local treatments for metastases of renal cell carcinoma: a systematic review, Lancet Oncol, 15, e549, 10.1016/S1470-2045(14)70235-9 Apollonio, 2019, The role of metastasectomy in advanced renal cell carcinoma, Expert Rev Anticancer Ther, 19, 603, 10.1080/14737140.2019.1625772 Mennitto, 2017, Multimodal treatment of advanced renal cancer in 2017, Expert Rev Clin Pharmacol, 10, 1395, 10.1080/17512433.2017.1386552 Larcher, 2019, Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates?, Eur Urol Oncol, 2, 365, 10.1016/j.euo.2019.04.007 Ouzaid, 2019, Surgical metastasectomy in renal cell carcinoma: a systematic review, Eur Urol Oncol, 2, 141, 10.1016/j.euo.2018.08.028 Bex, 2016, Role of targeted therapy in combination with surgery in renal cell carcinoma, Int J Urol, 23, 5, 10.1111/iju.12891 Daliani, 2009, Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma, BJU Int, 104, 456, 10.1111/j.1464-410X.2009.08490.x Husillos Alonso, 2015, Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?, World J Nephrol, 4, 254, 10.5527/wjn.v4.i2.254 Appleman, 2019, Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer research group (E2810), J Clin Oncol, 37, 4502, 10.1200/JCO.2019.37.15_suppl.4502 Fergusson, 2002, Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis, BMJ, 325, 652, 10.1136/bmj.325.7365.652 Procopio, 2018, A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (so) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial, J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.4502 Haas, 2016, Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial, Lancet, 387, 2008, 10.1016/S0140-6736(16)00559-6 Iacovelli, 2016, Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents, Crit Rev Oncol Hematol, 99, 324, 10.1016/j.critrevonc.2016.01.014